LPCAT4

Across TCGA pan-cancer cohorts, LPCAT4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LPCAT4 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LPCAT4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LPCAT4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

LUAD, PDAC, and COAD are the cancer types where LPCAT4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	0.444	0.810	.004	42	view →
PDAC	OS	Tertile	All	0.675	0.466	.009	21	view →
COAD	DFS	Median	III,IV	1.000	0.838	.036	12	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	6	view →
CCRCC	OS	Median	II,III,IV	0.953	0.671	.020	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LPCAT4–LUAD (OS)

Open the LUAD breakdown →